Abstract
SL3-3 is a highly T-lymphomagenic murine retrovirus in which the transcriptional enhancer is a major oncogenic determinant. Here, we describe an SL3-3 enhancer variant that induced T-cell lymphomas in all inoculated mice with a shorter latency period than wild-type SL3-3. The enhancer repeat region of this variant contains two deletions encompassing the nuclear factor 1 binding sites in addition to an additional intact enhancer repeat element. Tumors induced by this variant were T-cell lymphomas, as indicated by T-cell receptor rearrangements, and contained the input provirus enhancer regions. The variant was the result of mutation of specific transcription factor binding sites in the viral enhancer, isolation of rare second-site enhancer variants from the resulting induced tumors, and subsequent restoration of the original first-site mutations of one such variant. We have termed this process assisted molecular evolution.
Full Text
The Full Text of this article is available as a PDF (164.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Amtoft H. W., Sørensen A. B., Bareil C., Schmidt J., Luz A., Pedersen F. S. Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants. J Virol. 1997 Jul;71(7):5080–5087. doi: 10.1128/jvi.71.7.5080-5087.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Celander D., Hsu B. L., Haseltine W. A. Regulatory elements within the murine leukemia virus enhancer regions mediate glucocorticoid responsiveness. J Virol. 1988 Apr;62(4):1314–1322. doi: 10.1128/jvi.62.4.1314-1322.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ethelberg S., Hallberg B., Lovmand J., Schmidt J., Luz A., Grundström T., Pedersen F. S. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site. J Virol. 1997 Feb;71(2):1196–1206. doi: 10.1128/jvi.71.2.1196-1206.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ethelberg S., Lovmand J., Schmidt J., Luz A., Pedersen F. S. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo. J Virol. 1997 Oct;71(10):7273–7280. doi: 10.1128/jvi.71.10.7273-7280.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Golemis E. A., Speck N. A., Hopkins N. Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design. J Virol. 1990 Feb;64(2):534–542. doi: 10.1128/jvi.64.2.534-542.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hallberg B., Schmidt J., Luz A., Pedersen F. S., Grundström T. SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus. J Virol. 1991 Aug;65(8):4177–4181. doi: 10.1128/jvi.65.8.4177-4181.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morrison H. L., Soni B., Lenz J. Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus. J Virol. 1995 Jan;69(1):446–455. doi: 10.1128/jvi.69.1.446-455.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nielsen A. L., Norby P. L., Pedersen F. S., Jorgensen P. E-box sequence and context-dependent TAL1/SCL modulation of basic helix-loop-helix protein-mediated transcriptional activation. J Biol Chem. 1996 Dec 6;271(49):31463–31469. doi: 10.1074/jbc.271.49.31463. [DOI] [PubMed] [Google Scholar]
- Nielsen A. L., Nørby P. L., Pedersen F. S., Jørgensen P. Various modes of basic helix-loop-helix protein-mediated regulation of murine leukemia virus transcription in lymphoid cell lines. J Virol. 1996 Sep;70(9):5893–5901. doi: 10.1128/jvi.70.9.5893-5901.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nieves A., Levy L. S., Lenz J. Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3. J Virol. 1997 Feb;71(2):1213–1219. doi: 10.1128/jvi.71.2.1213-1219.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nilsson P., Hallberg B., Thornell A., Grundström T. Mutant analysis of protein interactions with a nuclear factor I binding site in the SL3-3 virus enhancer. Nucleic Acids Res. 1989 Jun 12;17(11):4061–4075. doi: 10.1093/nar/17.11.4061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schmidt J., Erfle V., Pedersen F. S., Rohmer H., Schetters H., Marquart K. H., Luz A. Oncogenic retrovirus from spontaneous murine osteomas. I. Isolation and biological characterization. J Gen Virol. 1984 Dec;65(Pt 12):2237–2248. doi: 10.1099/0022-1317-65-12-2237. [DOI] [PubMed] [Google Scholar]
- Speck N. A., Renjifo B., Golemis E., Fredrickson T. N., Hartley J. W., Hopkins N. Mutation of the core or adjacent LVb elements of the Moloney murine leukemia virus enhancer alters disease specificity. Genes Dev. 1990 Feb;4(2):233–242. doi: 10.1101/gad.4.2.233. [DOI] [PubMed] [Google Scholar]
- Thornell A., Hallberg B., Grundström T. Binding of SL3-3 enhancer factor 1 transcriptional activators to viral and chromosomal enhancer sequences. J Virol. 1991 Jan;65(1):42–50. doi: 10.1128/jvi.65.1.42-50.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zaiman A. L., Lenz J. Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb. J Virol. 1996 Aug;70(8):5618–5629. doi: 10.1128/jvi.70.8.5618-5629.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zaiman A. L., Lewis A. F., Crute B. E., Speck N. A., Lenz J. Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores. J Virol. 1995 May;69(5):2898–2906. doi: 10.1128/jvi.69.5.2898-2906.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]